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separation was 4.2, the sample  was .94, the item sepa-
ration was 3.0 and the item  was .90.
CONCLUSIONS: Our results suggest that the scale ap-
pears to measure a broad domain of psychological func-
tioning. Moreover, the scale appears to lack ceiling and
floor effects, and discriminated between inpatients, out-
patients, and non-patients, suggesting the scale has excel-
lent potential to be broadly responsive to a variety of
treatment effects.
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OBJECTIVE: Measure the impact of a PBM-adminis-
tered depression health management program based on
AHCPR guidelines on the prescribing behavior of clini-
cians using long-term antidepressant therapy.
METHOD: Doctors of patients at least 75% compliant
with antidepressant medication over the last 12 months
were identified (12/97 to 1/98) for a treatment education
intervention. Physicians (n  11,646) were mailed a one-
page summary of the AHCPR depression guidelines, a
patient-specific drug profile and diagnosis survey at the
13th month of antidepressant therapy. Non-responding
clinicians were called by trained pharmacists to secure
patient diagnosis and reinforce guidelines. Patients (n 
16,277) of the intervened-upon doctors were monitored
for antidepressant use at the 17th and 20th months (5
and 8 months after month 12, taken as baseline) follow-
ing their initial prescription. The control group (n 
36,954) was frequency-matched by drug, age, gender,
and region from a PBM prescription claims database.
RESULTS: The predominantly northeastern patient pop-
ulation was 59  13.6 years old and 70% female. With a
24% clinician response rate, 3.4% and 37.1%, respec-
tively, of patients were identified with first or recurrent
episodes of depression, and 29.7% as dysthymic or
chronic. Antidepressant usage was reduced 4.7% com-
pared to controls 5 months after baseline (p  0.001),
and 6.8% at 8 months. Among those identified, 16%
known first-episode, 12% recurrent and 10% dysthymic
depressed patients had discontinued therapy at 5 months.
At 8 months, the proportions were 14%, 15%, and 14%
respectively.
CONCLUSIONS: A PBM-administered guideline-based
depression treatment quality improvement program may
enhance clinical practice and lower the medication cost
of long-term depression therapy. While a higher propor-
tion of first-episode patients discontinued drug therapy at
5 months, the observed trend was not pronounced, possi-
bly due to clinician response bias. Subsequent analyses
will explore the program’s effect on relapse rates and
medical utilization.
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Inquiry into racial and gender differences have rarely fo-
cused on prescribing of new drug therapies.
OBJECTIVE: We examined the effect of race and gender
on the likelihood of being prescribed a new antidepres-
sant (fluoxetine versus existing antidepressants) in the
South Carolina Medicaid population.
METHODS: Patients were included in the study if they
had a primary physician or hospital diagnosis of depres-
sion (based on ICD-9-CMs) between January 1, 1988
and December 31, 1990 and if they had filled an antide-
pressant prescription within 4 months following the diag-
nosis. Selection of the study period was based on the year
fluoxetine entered the market (1987). A total of 1447 pa-
tients met the inclusion and exclusion criteria. Racial and
gender differences in prescribing patterns were deter-
mined using logistic regression, controlling for age, type
of county, provider type, Medicaid eligibility, physician
visits, and early filling of prescriptions.
RESULTS: Blacks were 30% less likely than whites
(OR  0.699; CI 0.540, 0.904, p  0.01) and males were
48% less likely than females to receive a fluoxetine pre-
scription.
CONCLUSION: Results demonstrated that there were sig-
nificant racial and gender differences in the utilization of
fluoxetine in the period immediately following its launch.
The findings should be interpreted with caution as poten-
tial confounding by disease severity, patient behavior, and
certain regional characteristics were not controlled.
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Managed care organizations are striving to seek ways to
provide cost-effective care for patients with major depres-
sion.
OBJECTIVE: The primary objective is to determine the
relationship between antidepressant utilization patterns
(treatment completion, switching, and augmentation)
and overall healthcare costs from a managed care per-
spective. The secondary objective is to investigate differ-
ences between specific antidepressants regarding these
outcomes. The inquiry is guided by the question: Which
factors contribute to overall healthcare service expendi-
tures for the treatment of depression?
METHODS: Retrospective computerized claims records
from a large managed care organization were analyzed
